Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Merck
Accenture
Chinese Patent Office
Fish and Richardson
Moodys
Federal Trade Commission
McKinsey
Mallinckrodt

Generated: June 23, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 202344

« Back to Dashboard

NDA 202344 describes BINOSTO, which is a drug marketed by Mission Pharma and is included in one NDA. It is available from one supplier. There are two patents protecting this drug. Additional details are available on the BINOSTO profile page.

The generic ingredient in BINOSTO is alendronate sodium. There are twenty-five drug master file entries for this compound. Thirty suppliers are listed for this compound. Additional details are available on the alendronate sodium profile page.
Summary for 202344
Tradename:BINOSTO
Applicant:Mission Pharma
Ingredient:alendronate sodium
Patents:2
Therapeutic Class:Metabolic Bone Disease Agents
Formulation / Manufacturing:see details
Pharmacology for NDA: 202344
Ingredient-typeDiphosphonates
Medical Subject Heading (MeSH) Categories for 202344
Suppliers and Packaging for NDA: 202344
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
BINOSTO alendronate sodium TABLET, EFFERVESCENT;ORAL 202344 NDA Mission Pharmacal Company 0178-0101 N 0178-0101-01
BINOSTO alendronate sodium TABLET, EFFERVESCENT;ORAL 202344 NDA Mission Pharmacal Company 0178-0101 N 0178-0101-02

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, EFFERVESCENT;ORALStrengthEQ 70MG BASE
Approval Date:Mar 12, 2012TE:RLD:Yes
Patent:➤ Sign UpPatent Expiration:Aug 11, 2023Product Flag?YSubstance Flag?YDelist Request?
Patent:➤ Sign UpPatent Expiration:Mar 6, 2023Product Flag?YSubstance Flag?YDelist Request?

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Teva
Federal Trade Commission
Cerilliant
Fish and Richardson
Chubb
Accenture
Boehringer Ingelheim
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.